IART:NASDAQIntegra LifeSciences Holdings Corporation analysis

Integra LifeSciences (IART) is trading at $17.77, comfortably above its 20‑day SMA of $16.01 and well above the 50‑day ($13.22) and 200‑day ($12.73) averages, indicating a strong bullish trend. The RSI sits at 68.4, suggesting the stock is approaching overbought territory, while the MACD histogram remains positive, confirming bullish momentum despite a recent decline in trading volume. Recent news shows the company beat Q1 revenue expectations with a 2.4% YoY increase to $391.9 M and posted a non‑GAAP EPS of $0.54, well above consensus, while leadership reshuffle brought back longtime chairman Stuart Essig as CEO, lending stability to the management team.
Fundamentally, IART trades at a forward P/E of 6.81 versus an industry average of 24.8, hinting at relative undervaluation, yet it carries a high debt‑to‑equity ratio of 195 and a negative profit margin of –30%, which tempers optimism. The forward EPS of $2.61 and reaffirmed full‑year revenue guidance ($1.662‑$1.702 B) support a “fair” valuation assessment, but the elevated 30‑day volatility (≈84%) and beta (~2.16) underscore considerable market risk.